Intrexon is engaged in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Using its suite of technologies, the company designs, builds and regulates gene programs, which are DNA sequences that consist of primary genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. The company's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary.
  • TickerXON
  • ISINUS46122T1025
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

ValuEngine Rating and Forecast Report for XON

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior